IO?
DEAD

Serial Number

87290975

Owner

BTG International Limited

Attorney

Lori S. Meddings

Filing Date

Jan 5, 2017

Add to watchlist:

No watchlists yet
View on USPTO

IO? Trademark

Serial Number: 87290975

IO? is a trademark filed by BTG International Limited on January 5, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

BTG International Limited (35 trademarks)

5 Fleet Place
London EC4M 7RD , GB

Entity Type: 11

Trademark Details

Filing Date

January 5, 2017

Registration Date

Not Registered

Published for Opposition

February 25, 2020

Goods & Services

(Based on 1(b)) Provision of education, namely, training in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision of education and training, namely, developing, arranging and conducting live and online educational conferences, seminars, classes, lectures, panel discussions, workshops and programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials in connection therewith; Provision of education and training, namely, providing non-downloadable webinars in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials in connection therewith; Provision of education and training, namely, conducting online and telephonic instruction and courses in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision of education and training, namely, development of multi-media educational content for use with mobile devices and computers in relation to healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Arranging, and conducting educational conferences and programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision and publication of educational material and content, namely, publication of teaching guides, instructional materials, brochures and providing on-line non-downloadable publications in the nature of teaching guides, instructional materials, and brochures in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Conducting educational seminars in the fields healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials therewith; Information and advice relating to education and training provided online from a computer database or the internet, all relating to healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision of educational information, namely, providing on-line instruction in the fields healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care provided on-line from a computer database

(Based on 44(e)) Pharmaceutical, medicinal and veterinary preparations and substances, namely, vaccines, antitoxic sera, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations and substances for the treatment of thrombosis, embolisms, inflammation, and autoimmune disease, pharmaceutical preparations for the treatment of envenomation by snakes, veterinary preparations for the treatment of envenomation by snakes, liquid medical sealants, and liquid adhesives for use in surgical and clinical procedure; sanitary preparations for medical purposes; vaccines; pharmaceutical and medicinal preparations and substances, namely, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances, and sepsis; medical diagnostic reagents and substances, all for in vivo use; antibodies and therapeutic antibodies for use as anti-lymphocytic agents for medical use; pharmaceutical preparations in the form of foams or for use in producing foams, for sclerotherapy, phlebology, angiology or proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; chemical reagents for medical or veterinary purposes; chemical reagents for medical therapeutic and diagnostic purposes; chemical reagents for medical and veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for use in the treatment of pre-eclampsia; chemical preparations for medical or pharmaceutical purposes for use in the prevention and treatment of cancer, circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, vascular issues and conditions, and intracranial hemorrhages, cerebral hemorrages, and hematoma; pharmaceutical preparations for the treatment of cancer; pharmaceutical and veterinary preparations for the reduction or elimination of circulating cytokines; pharmaceutical and veterinary preparations for the treatment of hypertension; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of multiple neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for the treatment of immune disorders, namely, type 1 diabetes, psoriasis, coeliac disease and rheumatoid arthritis; pharmaceutical preparations for the treatment of sepsis; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for treatment of envenomation by snakes; pharmaceutical preparations for the treatment of methotrexate toxicity; pharmaceutical preparations for the treatment of cancer including prostate, oesophageal and brain cancer and leukaemias; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolization; pharmaceutical preparations and substances for embolization of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical or veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemical preparations for medical or pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; chemical reagents for medical or veterinary therapeutic and medical diagnostic purposes; chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; chemical preparations for medical or pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; transarterial chemoembolization pharmaceutical preparations, vaccines and antitoxic sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticals, namely, radiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; Pharmaceutical preparations being beads, including microscopic radioactive beads, for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive material for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive pharmaceutical preparations and consisting of radioactive material for treatment of cancerous tumors; radioactive glass beads impregnated with pharmaceutical preparations for the treatment of cancer; irradiated and radioactive microspheres used for in vivo therapeutic medical purposes, namely, beads in the nature of microscopic glass beads impregnated with radioactive pharmaceutical preparations for treatment of cancerous tumors; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and/or medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams or for use in producing foams for sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; pharmaceutical preparations containing methotrexate antidotes; pharmaceutical preparations containing 5-fluorouracil antidotes; pharmaceutical preparations for use in chemotherapy and autoimmune diseases; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents

(Based on 1(b)) Provision of medical and surgical information; Provision of medical and surgical information on-line from a computer database or from the Internet or by telecommunication means; Providing medical information; Providing a website featuring information regarding medicine, medical treatment, medical patient care, therapeutic properties of prescription drugs, pharmaceutical advice, dispensing of pharmaceuticals, medical treatment and medical patient care aftercare; Providing a website featuring medical information regarding medicine, medical treatment, medical patient care, therapeutic properties of prescription drugs, pharmaceutical advice, dispensing of pharmaceuticals, medical treatment and medical patient care aftercare; Providing healthcare information; Providing information about medical devices for use in medical procedures and surgery; Providing information about healthcare; Providing information in the field of healthcare, therapeutic properties of pharmaceuticals, medical devices for use in medical procedures and surgery, surgery, and medicine and medical patient care; Providing information in the field of healthcare, therapeutic properties of pharmaceuticals, medical devices for use in medical procedures and surgery, surgery, and medicine and medical patient care by means of computer, electronic and online databases

(Based on 44(e)) Surgical, medical, dental and veterinary apparatus and instruments, namely, cryoablation needles, medical syringes, electrically powered tissue ablation devices, artificial limbs, orthopaedic articles, namely, implants made of artificial materials, haemofiltration devices for medical use, apparatus for generating and transmitting ultrasound for medical and diagnostic use, surgical and medical apparatus and instruments for use in minimally invasive cryoablation procedures, electronic apparatus and instruments for use in relation to ultrasound imaging and scanning for medical and diagnostic use, and medical and diagnostic imaging units; Surgical and medical apparatus, instruments and devices for the treatment of chronic lung disease including emphysema; medical syringes, medical cannula needles, medical tubing; surgical and medical apparatus for producing and administering pharmaceutical foams; surgical and medical apparatus and instruments for producing and administering sclerosing foams; surgical and medical apparatus and instruments for producing foams for use in sclerotherapy, phlebology, angiology or proctology, sterilisation treatment or for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; surgical and medical devices for assessing the physical characteristics of such foams, namely, devices for intravenous administration of foam, medical diagnostic apparatus for analyzing the efficacy of sclerotherapy foams for medical purposes, medical diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose, and devices for monitoring the position and effect of foam in the human body; medical diagnostic devices for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins, hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; drug delivery embolisation apparatus, instruments and systems; apparatus and instruments for use in the circulatory system; apparatus and instruments for embolisation; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems comprising surgical and medical instruments for embolisation; drug delivery embolisation systems; drug delivery apparatus and instruments comprised of injection syringes, and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials; medical apparatus and instruments for embolisation, namely, medical devices in the nature of particles, namely, embolic microspheres for embolization; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; beads, namely, microscopic glass beads, impregnated with radioactive material or containing radioactive material and administered surgically for treatment of cancerous tumours; radioactive beads, namely, radioactive glass beads administered for treatment of cancerous tumours; surgical and medical apparatus and instruments for use in the circulatory system; medical devices which use ultrasound to enhance drug delivery and/or medically activate drugs; catheters for delivery of drugs or fluids sold together as a unit with controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus sold together as a unit with controllers and power units therefor; needles for medical use, namely, cannula needles; medical tubing for sclerotherapy; medical tubing for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering sclerosing foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; syringes for producing and administering foams for use in sclerotherapy, phlebology, angiology or proctology; surgical and medical apparatus for administering and producing foams for use in sterilisation treatment; surgical and medical apparatus for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hycroceles; syringes for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; medical devices for intravenous administration of sclerosing foam for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical devices for monitoring the position and effect of foam in the human body; medical diagnostic apparatus for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins, hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; compression bandages; surgical instruments and apparatus and medical diagnostic apparatus for use in interventional pulmonology; medical devices for use in pulmonary and thoracic surgery and procedures; medical devices for use in pulmonary and thoracic surgery, namely, lung volume reduction devices; artificial surgical implants for use in interventional pulmonology; surgical implants comprising artificial surgical implants for restoring, maintaining and improving patient breathing, and artificial surgical implants for restoring, maintaining and improving lung function; medical devices for performing cryotherapy, namely, cryosurgical probes and cryoablation needles used for the minimally invasive cryoablation of cancerous and benign tissues; medical apparatus consisting of treatment probes and high pressure valves used for heat or freeze treatment incorporating computer software; surgical instruments and apparatus and medical diagnostic apparatus for use in cryoablation, and the treatment of prostate cancer, kidney or renal tumours, and benign prostatic hyperplasia (BPH ); medical devices used to deliver heat to target sites using electrical current through needles; medical devices to deliver cryogen gas for freezing and either cryogen gas or electrical current for heating for treatment of cancer and tumors; medical devices for ablating human and animal tissue using microwave energy; medical devices for treating cancerous and benign tissue using microwave energy; replacement and structural parts and fittings for all of the aforesaid goods

(Based on 1(b)) Providing on-line, non-downloadable educational software featuring instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; Information about medical research; Providing educational information in the field of medical research; Providing educational information in the field of medical research by means of computer, electronic and online databases; Information about pharmaceutical research; Providing educational information in the field of pharmaceutical research; Providing educational information in the field of pharmaceutical research by means of computer, electronic and online databases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
May 22, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 22, 2023 ABN6
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 16, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 16, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 16, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 16, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 16, 2023 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 19, 2022 EXRA
SOU EXTENSION 5 GRANTED
Aug 18, 2022 EX5G
SOU EXTENSION 5 FILED
Aug 17, 2022 EXT5
SOU TEAS EXTENSION RECEIVED
Aug 17, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2022 EXRA
SOU EXTENSION 4 GRANTED
Mar 3, 2022 EX4G
SOU EXTENSION 4 FILED
Feb 24, 2022 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 24, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 7, 2021 EXRA
SOU EXTENSION 3 GRANTED
Oct 6, 2021 EX3G
SOU EXTENSION 3 FILED
Oct 5, 2021 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 5, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 29, 2021 EXRA
SOU EXTENSION 2 GRANTED
Apr 28, 2021 EX2G
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 1, 2021 EXRA
SOU EXTENSION 2 FILED
Mar 29, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 29, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 23, 2021 EXRA
SOU EXTENSION 1 GRANTED
Mar 22, 2021 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 22, 2021 AITU
NOTICE OF REVIVAL - E-MAILED
Jan 11, 2021 NREV
SOU EXTENSION RECEIVED WITH TEAS PETITION
Jan 11, 2021 TPEX
PETITION TO REVIVE-GRANTED
Jan 11, 2021 PETG
TEAS PETITION TO REVIVE RECEIVED
Jan 11, 2021 PROA
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 23, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 23, 2020 ABN6
SOU EXTENSION 1 FILED
Oct 21, 2020 EXT1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 30, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 30, 2020 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Aug 30, 2020 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 30, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 30, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 30, 2020 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 21, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 25, 2020 NPUB
PUBLISHED FOR OPPOSITION
Feb 25, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 5, 2020 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 23, 2020 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 16, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 15, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 15, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 15, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 15, 2020 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 31, 2019 GNRN
NON-FINAL ACTION E-MAILED
Dec 31, 2019 GNRT
NON-FINAL ACTION WRITTEN
Dec 31, 2019 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Dec 10, 2019 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Nov 12, 2019 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 29, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 3, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 3, 2019 CRFA
EXAMINER'S AMENDMENT ENTERED
Sep 27, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 27, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 27, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 27, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 26, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 26, 2019 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 23, 2019 ERFR
EX PARTE APPEAL-INSTITUTED
Aug 23, 2019 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Aug 23, 2019 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Aug 23, 2019 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 25, 2019 GNFN
FINAL REFUSAL E-MAILED
Feb 25, 2019 GNFR
FINAL REFUSAL WRITTEN
Feb 25, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 4, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 4, 2019 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 1, 2019 ERSI
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 2, 2018 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 18, 2018 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 8, 2018 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 7, 2018 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 2, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 2, 2017 GNSL
SUSPENSION LETTER WRITTEN
Sep 2, 2017 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 23, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 22, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 22, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 7, 2017 GNRN
NON-FINAL ACTION E-MAILED
Mar 7, 2017 GNRT
NON-FINAL ACTION WRITTEN
Mar 7, 2017 CNRT
ASSIGNED TO EXAMINER
Mar 4, 2017 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Feb 10, 2017 AMPX
ASSIGNED TO LIE
Feb 9, 2017 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Jan 27, 2017 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 13, 2017 NWOS
NEW APPLICATION ENTERED
Jan 9, 2017 NWAP